Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) announced its earnings results on Friday. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, Zacks reports.
Titan Pharmaceuticals Stock Performance
TTNP stock traded up $0.04 during trading on Friday, reaching $3.23. The stock had a trading volume of 17,299 shares, compared to its average volume of 19,230. The firm has a fifty day moving average price of $3.74 and a 200 day moving average price of $4.99. Titan Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $14.80.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on shares of Titan Pharmaceuticals in a research note on Friday, December 27th. They issued a “sell” rating for the company.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- 3 Stocks to Consider Buying in October
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
